` SNSE (Sensei Biotherapeutics Inc) vs S&P 500 Comparison - Alpha Spread

SNSE
vs
S&P 500

Over the past 12 months, SNSE has underperformed S&P 500, delivering a return of -35% compared to the S&P 500's +13% growth.

Stocks Performance
SNSE vs S&P 500

Loading
SNSE
S&P 500
Add Stock

Performance Gap
SNSE vs S&P 500

Performance Gap Between SNSE and GSPC
HIDDEN
Show

Performance By Year
SNSE vs S&P 500

Loading
SNSE
S&P 500
Add Stock

Competitors Performance
Sensei Biotherapeutics Inc vs Peers

S&P 500
SNSE
ABBV
AMGN
GILD
VRTX
Add Stock

Sensei Biotherapeutics Inc
Glance View

Market Cap
10.1m USD
Industry
Biotechnology

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 56 full-time employees. The company went IPO on 2021-02-04. The firm is engaged in the discovery and development of therapies with focus on treatments for cancer. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. The firm is engineering its ImmunoPhage product candidates to directly target antigen presenting cells (APCs) and modulate the tumor microenvironment (TME) through the targeted use of nanobodies which enhances therapeutic activity. SNS-301 is an ImmunoPhage product candidate that the Company is developing as a treatment for locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN). The company also develops ImmunoPhage candidate, SNS-401, for the treatment of Merkel cell carcinoma (MCC). The firm is also engaged in developing a monoclonal antibody (mAb) therapy.

SNSE Intrinsic Value
HIDDEN
Show
Back to Top